LXEO (Lexeo Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LXEO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Jose Manuel Otero | Chief Operating Officer | Sell | — | — |
| 2026-08-19 | Louis Edward Tamayo | Chief Financial Officer | Sell | — | — |
| 2026-08-19 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2026-07-01 | Louis Edward Tamayo | Chief Financial Officer | MIXED | — | — |
| 2026-07-01 | Narinder Pal Bhalla | Chief Medical Officer | MIXED | — | — |
| 2026-07-01 | Jose Manuel Otero | Chief Operating Officer | MIXED | — | — |
| 2026-07-01 | Richard Nolan Townsend | Chief Executive Officer | MIXED | — | — |
| 2026-06-29 | REINALDO M DIAZ | Director | A | — | — |
| 2026-06-29 | Timothy Van Hauwermeiren | Director | A | — | — |
| 2026-06-29 | Steven Altschuler | Director | A | — | — |
| 2026-06-29 | Mette Kirstine Agger | Director | A | — | — |
| 2026-06-29 | Tolga Tanguler | Director | A | — | — |
| 2026-06-29 | PAULA H CHOLMONDELEY | Director | A | — | — |
| 2026-06-29 | BRENDA COOPERSTONE | Director | A | — | — |
| 2026-05-20 | Jose Manuel Otero | Chief Operating Officer | Sell | — | — |
| 2026-05-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2026-04-07 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2026-03-17 | Jose Manuel Otero | Chief Operating Officer | A | — | — |
| 2026-03-17 | Richard Nolan Townsend | Chief Executive Officer | A | — | — |
| 2026-02-20 | Jose Manuel Otero | Chief Operating Officer | Sell | — | — |
| 2026-02-20 | Jose Manuel Otero | Chief Operating Officer | Sell | — | — |
| 2026-02-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2026-02-17 | Narinder Pal Bhalla | Chief Medical Officer | A | — | — |
| 2026-02-06 | Louis Edward Tamayo | Chief Financial Officer | A | — | — |
| 2026-02-06 | Richard Nolan Townsend | Chief Executive Officer | A | — | — |
| 2026-02-06 | Jose Manuel Otero | Chief Operating Officer | A | — | — |
| 2025-11-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2025-11-20 | Eric Adler | Chief Medical Officer | Sell | — | — |
| 2025-11-20 | Jose Manuel Otero | Chief Technical Officer | Sell | — | — |
| 2025-11-20 | Jenny Robertson | Chief Legal Officer | Sell | — | — |
| 2025-11-20 | Tai Sandi See | Chief Development Officer | Sell | — | — |
| 2025-10-17 | Jenny Robertson | Chief Legal Officer | MIXED | — | — |
| 2025-10-17 | Richard Nolan Townsend | Chief Executive Officer | MIXED | — | — |
| 2025-10-17 | Eric Adler | Chief Medical Officer | MIXED | — | — |
| 2025-10-17 | Tai Sandi See | Chief Development Officer | MIXED | — | — |
| 2025-10-17 | Jose Manuel Otero | Chief Technical Officer | MIXED | — | — |
| 2025-09-16 | Richard Nolan Townsend | Chief Executive Officer | A | — | — |
| 2025-09-10 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2025-09-03 | Louis Edward Tamayo | Chief Financial Officer | A | — | — |
| 2025-08-20 | Eric Adler | Chief Medical Officer | Sell | — | — |
| 2025-08-20 | Jenny Robertson | Chief Legal Officer | Sell | — | — |
| 2025-08-20 | Tai Sandi See | Chief Development Officer | Sell | — | — |
| 2025-08-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | — | — |
| 2025-08-20 | Jose Manuel Otero | Chief Technical Officer | Sell | — | — |
| 2025-06-30 | BRENDA COOPERSTONE | Director | A | — | — |
| 2025-06-30 | PAULA H CHOLMONDELEY | Director | A | — | — |
| 2025-06-30 | Tolga Tanguler | Director | A | — | — |
| 2025-06-30 | Mette Kirstine Agger | Director | A | — | — |
| 2025-06-30 | REINALDO M DIAZ | Director | A | — | — |
| 2025-06-30 | Steven Altschuler | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,112,555 | — |
| — | 10%+ Owner | 1,835,959 | — |
| — | 10%+ Owner | 1,703,078 | — |
| — | Chief Executive Officer | 374,472 | — |
| — | Chief Operating Officer | 136,178 | — |
| — | Chief Financial Officer | 92,907 | — |
| — | Chief Medical Officer | 82,194 | — |
| — | Chief Medical Officer | 72,646 | — |
| — | Chief Legal Officer | 68,381 | — |
| — | Chief Development Officer | 65,476 | — |
| — | Chief Financial Officer | 40,875 | — |
| — | Director | 30,627 | — |
| — | Chief Technical Officer | 17,349 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LXEO quote page; the site-wide leaderboard is on the insider transactions hub.